Mobile

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Mise à jour : Il y a 4 ans
Référence : NCT01928537

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.

Critère d'inclusion

  • Myelodysplastic syndromes,Refractory Anemia With Excess Blasts,Chronic myelomonocytic leukemia,Cytopenia

Liens